Grifols Signs a License and Commercialization Agreement with Rigel Pharmaceuticals for Fostamatinib

 Grifols Signs a License and Commercialization Agreement with Rigel Pharmaceuticals for Fostamatinib

Grifols Signs a License and Commercialization Agreement with Rigel Pharmaceuticals for Fostamatinib

Shots:

  • Rigel to receive $30M upfront, $297.5M milestones including $20M on EMA approval of fostamatinib and royalties up to 30% on net sales. Grifols to get exclusive rights for fostamatinib in all indications including chronic ITP, autoimmune hemolytic anemia (AIHA), and IgA nephropathy (IgAN), in EU and Turkey
  • Rigel will retain all global rights for fostamatinib (Ex- EU & Turkey) and will pay $25M to regain rights for fostamatinib in EU and other territories to Grifols. Grifols will have an option to terminate the agreement in six-months
  • Fostamatinib is a novel SYK inhibitor approved for thrombocytopenia & chronic immune thrombocytopenia in adult, marketed as Tavalisse (fostamatinib disodium hexahydrate) in the US and has received EMA’s approval for chronic ITP on 4 Oct, 2018

Click here to read full press release/ article | Ref: PRN Newswire | Image: The corner

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post